Drug Companies: A Powerhouse of Profits

by The Investment U Research Team

A couple of interesting news items came out in the past few days. One, a research report showing how expensive treatment is for childhood mental issues. It also showed that in 2006 over 13 million children were treated for asthma at a cost of $8 billion.

The other a study that finds more Americans than ever are taking some sort of prescription for mental illness – 73% more than in 1996.

What’s interesting, apart from the fact that we seem to be overmedicating as a society, is that the numbers of patients and the costs of treatments spell hundreds of billions in profits for healthcare and drug makers.

Taking a look at the eleven largest, we find that their market caps total almost $900 billion. That’s a trillion dollars in market value within a handful of companies.

Merck and Co. (NYSE: MRK), Schering-Plough (NYSE: SGP), GlaxoSmithKline ADR (NYSE: GSK), Bristol Myers Squibb (NYSE: BMY) Sanofi-Aventis ADR (NYSE: SNY), AstraZeneca ADR (NYSE: AZN), Johnson & Johnson (NYSE: JNJ), Roche Holding Ltd ADR (OTC: RHHBY) Novartis AG ADR (NYSE: NVS), Eli Lilly & Co (NYSE: LLY) and Wyeth (NYSE: WYE) represent a powerhouse of pharmaceuticals and drug development.

And while we’ve talked before about the potential for mega-mergers, looking at the size of the playing field one discovers that for the most part, these companies are relatively the same size.

The question is whether by merging, and growing larger they will be able to cut redundant overhead for these transactions to make sense. Is there a market cap size where these firms are able to run most effectively, most efficiently, and most profitably?

Companies mentioned in this article: MRK, SGP, GSK, BMY, SNY, AZN, JNJ, RHHBY, LLY and WYE

• Two Pharmas Are Better Than One… Here Are the Ones to Buy in This Merger-Mad Industry
• Emerging Market for Pharma
• Increasing Alzheimer’s Patients Spell Drug Profits

Sign Up now and receive this Free report: Collect 122% in the Next 12 Months From Gold's Surge.

The Single Best Investment for 2009

Forget another stimulus package. Or retreating into "safe-havens" like cash and gold. All you need in 2009 is a small exposure to the "secret" White Cap Index.

It's up as much as 171% straight through Wall Street's meltdown. And one of the latest stocks to be added - an Internet-related venture capital company - is up over 100% since its inclusion into the Index.

Just weeks from now, we'll add another White Cap stock to this market-trouncing index. To get a sneak peek, click here for full details.

Comments

Check out our selection of daily Investment Research:

We Respect Your Privacy

---

What is Investment U?

Since 1999, Investment U has provided impartial, no-nonsense investment advice on how to build long-lasting wealth.

---

Recent Articles

Platinum Services

The Oxford Club is an exclusive, global network of investors, who collectively participate in the pursuit of prosperity and wealth. The Club is renowned for its market-beating, tried-and-true investment principles.

The White Cap Report exclusively identifies companies, White Caps, which - by being among the earliest to gain traction - have secured dominant positions within untapped, billion-dollar markets.

With an elite trading team at the helm, the Xcelerated Profits Report shows any investor how to "invest like a pro," using high-level, yet easy-to-execute strategies that "xcelerate" profits while minimizing risk.

---